Exciting to hear about 5 trials for #GCA 1. ABAGART (#Abatacept) 2. METOGIA (#tocilizumab vs MTX) 3. SELECT (#upadacitinib) 4. MAVRILIMUMAB (#gmcsf i) 5. TiTIAN (#secukinumab) ⁦@VasculitisFound⁩ #vasculitis #vcrc https://t.co/DVvG5Ekfu9